LUCD Lucid Diagnostics Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1799011 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY23.6%
TTM net income YoY8.9%
TTM EPS YoY—
Revenue 3-yr CAGR53.6%
Net income 3-yr CAGR—
Margins
Gross margin-16.5%
Operating margin-941.7%
Net margin-892.8%
FCF margin-953.3%
EBITDA margin-925.5%
Returns
ROE-305.6%
ROA-119.8%
ROIC (approx.)—
Asset turnover0.13x
Leverage & solvency
Liabilities / assets78.7%
Debt / equity0.00x
Current ratio1.20x
Interest coverage-3,011.88x
Cash quality & payout
Operating cash flow / net income1.06x
Accruals ratio7.4%
Payout ratio—
Capex / revenue5.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $4.71M | $4.35M |
| Cost of revenue | $6.67M | $7.10M |
| Gross profit | -$1.96M | -$2.75M |
| R&D expense | $5.68M | $5.99M |
| SG&A expense | $23.87M | $20.16M |
| Operating income | -$49.64M | -$46.05M |
| Interest expense | $22,000 | $26,000 |
| Pretax income | -$58.01M | -$45.53M |
| Income tax | $0 | $0 |
| Net income | -$58.01M | -$45.53M |
| EBITDA | -$48.77M | -$44.88M |
| EPS (basic) | -0.69 | -1.05 |
| EPS (diluted) | — | -1.05 |
| Weighted avg. shares (diluted) | — | 50.52M |
| Balance sheet | ||
| Cash & equivalents | $34.70M | $22.36M |
| Receivables | $643,000 | $45,000 |
| Inventory | $353,000 | $341,000 |
| Current assets | $37.47M | $25.15M |
| PP&E, net | $809,000 | $1.06M |
| Intangibles | $315,000 | $736,000 |
| Total assets | $40.45M | $30.71M |
| Current liabilities | $28.58M | $23.52M |
| Total liabilities | $29.51M | $25.32M |
| Shareholders' equity | $10.94M | $5.39M |
| Shares outstanding | 131.10M | 63.07M |
| Cash flow statement | ||
| Operating cash flow | -$46.48M | -$44.14M |
| Capital expenditure | $197,000 | $296,000 |
| Free cash flow | -$46.68M | -$44.44M |
| Investing cash flow | -$197,000 | -$646,000 |
| Financing cash flow | $59.03M | $48.25M |
| Depreciation & amortization | $872,000 | $1.17M |
| Stock-based compensation | $4.49M | $4.53M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.